The earnings call highlighted strong sales performance and strategic achievements, such as the launch of Zevtera in the U.S. and significant funding secured. However, challenges include decreased net profit due to past tax benefits, rising operating expenses, and an anticipated decline in product revenue due to reduced supply to Pfizer. The overall sentiment suggests a positive outlook with some caution due to financial pressures.

Company Guidance -

Q4 2025

During the Basilea Pharmaceutica Half Year Results 2025 Conference Call, the company provided updated financial guidance for the year, highlighting a projected total revenue increase to CHF 225 million, up from the previously communicated CHF 220 million. Revenue from Cresemba and Zevtera is expected to reach around CHF 190 million, with a 14% growth in royalty income to CHF 110 million. Operating profit for 2025 is anticipated to be approximately CHF 50 million. R&D expenses are set to rise to CHF 105 million, primarily due to in-licensing ceftibuten-ledaborbactam, adding CHF 15 million in expenses. The company also reported a positive net cash position of CHF 50.7 million as of June 30, 2025, and highlighted the strong performance of Cresemba, with in-market sales reaching USD 612 million, a 25% year-on-year increase.

Impressive Sales Growth for Cresemba

Cresemba achieved a 24.8% increase in global in-market sales for the 12 months to March 2025 and a 21.7% increase in royalty income year-on-year.

Strong Financial Performance

Basilea reported a positive operating result of CHF 24 million for the first half of 2025, with total revenue increasing by 36% compared to the first half of 2024.

Secured Additional Funding

Basilea secured USD 39 million in nondilutive funding from BARDA to support the development of antifungal candidates.

Strategic In-Licensing

Basilea in-licensed ceftibuten-ledaborbactam, a Phase III-ready oral antibiotic for complicated urinary tract infections.

Zevtera U.S. Launch

Zevtera was successfully launched in the U.S., marking a key commercial milestone.

Basilea Pharmaceutica (CH:BSLN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CH:BSLN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 17, 2026	2025 (Q4)	3.07 / -	4.7	―	―	―
Aug 19, 2025	2025 (Q2)	2.03 / 1.26	1.575	-20.00% (-0.31)	―	―
Feb 18, 2025	2024 (Q4)	3.24 / 4.70	-1.705	375.66% (+6.41)	―	―
Aug 13, 2024	2024 (Q2)	1.17 / 1.57	2.431	-35.21% (-0.86)	―	―
Feb 13, 2024	2023 (Q4)	-2.02 / -1.71	2.05	-183.17% (-3.75)	―	―
Aug 15, 2023	2023 (Q2)	0.81 / 2.43	-1.03	336.02% (+3.46)	―	―
Feb 14, 2023	2022 (Q4)	-1.30 / 2.05	1.26	62.70% (+0.79)	―	―
Aug 16, 2022	2022 (Q2)	-1.55 / -1.03	-1.84	44.02% (+0.81)	―	―
Feb 15, 2022	2021 (Q4)	0.07 / 1.26	-2.34	153.85% (+3.60)	―	―
Aug 16, 2021	2021 (Q2)	-0.82 / -1.84	0.91	-302.20% (-2.75)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CH:BSLN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 19, 2025	CHF52.90	CHF48.90	-7.56%
Feb 18, 2025	CHF40.85	CHF44.25	+8.32%
Aug 13, 2024	CHF37.85	CHF41.00	+8.32%
Feb 13, 2024	CHF33.55	CHF36.50	+8.79%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Basilea Pharmaceutica (CH:BSLN) report earnings?

Basilea Pharmaceutica (CH:BSLN) is schdueled to report earning on Feb 17, 2026, TBA (Confirmed).

What is Basilea Pharmaceutica (CH:BSLN) earnings time?

Basilea Pharmaceutica (CH:BSLN) earnings time is at Feb 17, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Basilea Pharmaceutica stock?

The P/E ratio of Basilea Pharmaceutica is N/A.

What is CH:BSLN EPS forecast?

CH:BSLN EPS forecast for the fiscal quarter 2025 (Q4) is 3.07.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing